Stem Cell Banking Market Is Booming Across the Globe Explored in Latest Research 2017-2025
Stem cells have the potential to transform to any tissue or organ in the body. Stem cells can be found in bone marrow, fetal tissues, baby teeth, fat, human embryos, hair follicles, muscle, and circulating blood, however, cord blood is an effective source of stem cells. Stem cells from cord blood are preferred due to various advantages such as efficacy in transplant due to less chances of immune rejection during the transfusion. Numerous applications of stem cells such as treatment in various diseases such as cancer, have led to demand for stem cell banking. These stem cells are collected from humans and preserved for the future use.
Request a Sample Copy of This Business Report : https://www.coherentmarketinsights.com/insight/request-sample/1354
Increasing incidences of chronic disease and the effectiveness of stem cell therapy in the treatment of such diseases is a major driving factor for growth of stem cell banking market. According to the survey by Seattle Children’s Hospital and Research Center, 2013, the survival rate of patient with cancer after stem cell transplant for period of one year was 84% globally. Growing public awareness for stem cell storage is also contributing to stem cell banking market growth. Additionally, new clinical trial data that supports applications for hematopoietic stem cells from mesenchymal stem cells and cord blood is expected to help in growth of stem cell banking market. Moreover, various organizations are supporting stem cell banking, which is expected to aid in growth of the market. For instance, in 2012, Harvard University and University of Cambridge announced plans to set up a new stem cells research center, funded by Medical Trust UK and UK Medical Research Council, to conduct research on stem cells and their potential to treat a range of life-threatening conditions.
High therapeutic potential of stem cells for treating genetic diseases is expected to aid in growth of the market
High potential of cord blood and tissues for the treatment of patients with autoimmune diseases is expected to propel the market growth. Moreover, currently available immunosuppressive agents such as steroids, induce long term side effects despite temporary improvements. According to the Health Research Funding, 2015, around 28% of cord blood transplants have been used to treat genetic diseases, with the most common genetic disease treated being severe combined immune deficiency, followed by aplastic anemia. According to the National Cord Blood Program, 2015, cord blood from unrelated donors has been used as an alternative to bone marrow or mobilized stem cells, as a source of hematopoietic stem cells, with over 35,000 stem cell transplants successfully performed worldwide. Stem cells can be stored indefinitely and can easily retain viability even after a decade of storage and this is a major factor driving growth of the market.
Major players operating in the global stem cell banking market are Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.
Ask For The PDF Sample : https://www.coherentmarketinsights.com/insight/request-sample/1354
- Global Stem Cell Banking Market, By Source Type:
- Cord Blood
- Cord Tissue
- Global Stem Cell Banking Market, By Service Type:
- Collection and Transportation
- Global Stem Cell Banking Market, By Application:
- Cerebral Palsy
Asia Pacific is expected to exhibit significant growth in the global stem cells banking market over the forecast period. This is owing to rising birth rates coupled with increasing prevalence of birth defects, and options of paying for stem banking in monthly instalments, making it accessible to a number of people. For instance, according to the survey by Save the Children India, 2012, India has a booming birth rate of 26 million per year and this is aiding in growth of the market. According to Multicenter Study, 2013, about 10,000 to 15,000 infants are diagnosed suffering from thalassemia and sickle cell anemia in India, indicating high demand for stem cells banking.